Skip Navigation

JNCI Journal of the National Cancer Institute 2008 100(21):1485; doi:10.1093/jnci/djn398
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

In This Issue

The first 10% of the full text of this article appears below.

Guidelines for Testing Anticancer Drugs in Rodents

Rodent models are commonly used to test the in vivo efficacy of new compounds that have anticancer activity in vitro. However, if experiments using such models are not designed appropriately, there is the potential for both false-negative and false-positive results—a consideration that is especially important given the cost and time needed for rodent studies and the use of these studies to determine which drugs to pursue for development. In this issue, Hollingshead (p. 1500) discusses a number of issues that should be addressed when designing experiments using rodent models, including identification of appropriate species and tumor models (and controls), selection of . . . [Full Text of this Article]

Statin Use and PSA Level

X Chromosome Inactivation in Breast and Ovarian Cancer

Evaluating the Impact of Cancer Scale

Characteristics and Treatment Patterns of MDS Patients

Association of a Genetic Locus with Risk of Lung Cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Refinement and Psychometric Evaluation of the Impact of Cancer Scale
Catherine M. Crespi, Patricia A. Ganz, Laura Petersen, Adrienne Castillo, and Bette Caan
J Natl Cancer Inst 2008 100: 1530-1541. [Abstract] [Full Text] [PDF]

Skewed X Chromosome Inactivation and Breast and Ovarian Cancer Status: Evidence for X-Linked Modifiers of BRCA1
Felicity Lose, David L. Duffy, Graham F. Kay, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Australian Ovarian Cancer Study Management Group, Mary A. Kedda, and Amanda B. Spurdle
J Natl Cancer Inst 2008 100: 1519-1529. [Abstract] [Full Text] [PDF]

Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys
Mikkael A. Sekeres, W. Marieke Schoonen, Hagop Kantarjian, Alan List, Jon Fryzek, Ronald Paquette, and Jaroslaw P. Maciejewski
J Natl Cancer Inst 2008 100: 1542-1551. [Abstract] [Full Text] [PDF]

Antitumor Efficacy Testing in Rodents
Melinda G. Hollingshead
J Natl Cancer Inst 2008 100: 1500-1510. [Abstract] [Full Text] [PDF]

The Influence of Statin Medications on Prostate-specific Antigen Levels
Robert J. Hamilton, Kenneth C. Goldberg, Elizabeth A. Platz, and Stephen J. Freedland
J Natl Cancer Inst 2008 100: 1511-1518. [Abstract] [Full Text] [PDF]

The CHRNA5-A3 Region on Chromosome 15q24-25.1 Is a Risk Factor Both for Nicotine Dependence and for Lung Cancer
Margaret R. Spitz, Christopher I. Amos, Qiong Dong, Jie Lin, and Xifeng Wu
J Natl Cancer Inst 2008 100: 1552-1556. [Abstract] [Full Text] [PDF]

Prostate-Specific Antigen: A Misused and Maligned Prostate Cancer Biomarker
Ian M. Thompson, Catherine M. Tangen, and Alan R. Kristal
J Natl Cancer Inst 2008 100: 1487-1488. [Extract] [Full Text] [PDF]

Intermediacy and Gene–Environment Interaction: The Example of CHRNA5-A3 Region, Smoking, Nicotine Dependence, and Lung Cancer
Sholom Wacholder, Nilanjan Chatterjee, and Neil Caporaso
J Natl Cancer Inst 2008 100: 1488-1491. [Extract] [Full Text] [PDF]